while several plasma biomarkers, such as CXCL13, CA-125, MMP7, SP-D, YKL-40, and VCAM-1, have been associated with prognostic survival in patients with ILD, these biomarkers are rarely utilized for assessing pulmonary function in clinical practice [21]. Here, CXCL13 is linked to interstitial lung disease.